Search
Buclizine
go.drugbank.com/drugs/DB00354ApprovedIt was manufactured by Stuart Pharms and initially approved by the FDA in 1957. … [L6217] Following this, it was touted to be effective as an appetite stimulant in children when administered in the syrup form, however, this indication has not been validated.
Teplizumab
go.drugbank.com/drugs/DB06606ApprovedInvestigational[A241490] Anti-CD3 therapy has traditionally been used to prevent graft-versus-host-disease in organ transplantation but more recently has been explored to prolong the onset of (T1D) in high-risk patients … [A241480] On November 2022, teplizumab was approved by the FDA as the first drug that can delay the onset of type 1 diabetes.
Doxorubicin
go.drugbank.com/drugs/DB00997ApprovedInvestigational[A257614] Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin … [A257709] Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and
Rotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalIt was approved by the European Medicines Agency in 2006 and by the FDA in 2007. … Rotigotine was developed by Aderis Pharmaceuticals. In 1998 Aderis licensed worldwide development and commercialization rights to Schwarz Pharma of Germany.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromePheniramine
go.drugbank.com/drugs/DB01620ApprovedPheniramine's use as an anti-allergy medication has largely been supplanted by second-generation antihistamines such as [cetirizine] and [loratadine]. … Pheniramine is a first-generation antihistamine in the alkylamine class, similar to [brompheniramine] and [chlorpheniramine].
Mixtures: Neo Citran Powder, Neo Citran A PowderAlirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalAlirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of … From this family, it was the first agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety.
Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaFebuxostat
go.drugbank.com/drugs/DB04854ApprovedInvestigationalFebuxostat is a non-purine xanthine oxidase (XO) inhibitor. … [L32238] Gout is a form of arthritis that is caused by the accumulation of uric acid crystal in or around a joint, leading to inflammation and further deposition of uric acid crystal deposition in bones
Testosterone cypionate
go.drugbank.com/drugs/DB13943ApprovedInvestigationalIt was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979. … Its benefit compared to other testosterone derivatives is the slow rate of release after injection and longer half-life.
Monopotassium phosphate
go.drugbank.com/drugs/DB09413ApprovedInvestigationalVet approvedIt can be used in fertilizer mixtures to reduce escape of ammonia by keeping pH low.
Mixtures: K-Phos No. 2, Dextrose and Electrolyte No. 75Ranibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalIn order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use. … [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.